Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 5Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

pembrolizumab 303Carboplatin 232Cisplatin 161Paclitaxel 154Gemcitabine 153Pemetrexed 123Bevacizumab 121Docetaxel 106durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 53Lenalidomide 51venetoclax 47Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × ravulizumab × 90 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT05644561 2026-04-17

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
12 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔